Nanobiotix (NASDAQ:NBTX) Trading 7.2% Higher – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price was up 7.2% during mid-day trading on Thursday . The company traded as high as $34.37 and last traded at $34.4980. Approximately 47,083 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 49,874 shares. The stock had previously closed at $32.19.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NBTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Finally, Guggenheim lifted their target price on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.00.

Nanobiotix Stock Performance

The company has a 50-day simple moving average of $30.77 and a two-hundred day simple moving average of $24.95.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $3.42 million during the quarter. Sell-side analysts forecast that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current fiscal year.

Institutional Trading of Nanobiotix

Several institutional investors and hedge funds have recently bought and sold shares of NBTX. Royal Bank of Canada raised its stake in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. bought a new position in shares of Nanobiotix during the 3rd quarter worth approximately $101,000. Marshall Wace LLP bought a new position in shares of Nanobiotix during the 4th quarter worth approximately $220,000. Finally, Millennium Management LLC bought a new position in shares of Nanobiotix during the 4th quarter worth approximately $390,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.